Efficacy

Efficacy of Perjeta (Pertuzumab) in Breast Cancer

Perjeta (Pertuzumab) is a monoclonal antibody that targets the HER2 receptor, a protein found in high quantities on the surface of some cancer cells in HER2-positive breast cancer. Pertuzumab is designed to prevent the HER2 receptors from pairing (dimerizing), which is a process that can promote the growth of cancer cells. When used in combination with trastuzumab and chemotherapy, Pertuzumab has been shown to significantly improve progression-free survival (PFS) and overall survival (OS) in patients with HER2-positive metastatic breast cancer. The efficacy of Pertuzumab in this setting was demonstrated in pivotal clinical trials such as the CLEOPATRA study, which reported a significant improvement in survival outcomes compared to the standard therapy alone.

In the neoadjuvant setting (treatment given before surgery), Pertuzumab has also been found to increase the rate of pathological complete response (pCR), which is the absence of invasive cancer in the breast and lymph nodes at the time of surgery. This outcome is associated with a better prognosis. Pertuzumab, in combination with trastuzumab and chemotherapy, has become a standard treatment option for patients with HER2-positive early breast cancer based on the results from trials like the NEOSPHERE and TRYPHAENA studies.

Efficacy of Orserdu (Elacestrant) in Breast Cancer

Orserdu (Elacestrant) is a selective estrogen receptor degrader (SERD) that is being investigated for the treatment of estrogen receptor-positive (ER+), HER2-negative advanced or metastatic breast cancer. While Orserdu has not yet been approved by regulatory agencies at the time of this writing, it has shown promise in clinical trials. The efficacy of Elacestrant is being evaluated in terms of its ability to inhibit the growth of breast cancer cells that are dependent on estrogen for growth and survival.

Early clinical trial results have suggested that Orserdu may be effective in patients who have previously been treated with endocrine therapy and CDK4/6 inhibitors, a common treatment regimen for ER+ breast cancer. The drug is designed to bind to the estrogen receptor, causing its degradation, which in turn can reduce the growth-promoting effects of estrogen on the cancer cells. Ongoing clinical trials aim to further establish the efficacy and safety profile of Elacestrant in this patient population, with the potential to offer a new treatment option for those with advanced breast cancer.